40789 Monheim am Rhein, de
+49 (2173) 4995-464
Cognis delighted about DHA and Vitamin E claim approvals - assessment for its CLA claim still pending
The EFSA's third batch of article 13.1 health claim opinions included good news for Cognis. There were three positive opinions on health claims concerning DHA - claims relating to normal brain function, normal vision, and maintaining normal (fasting) blood concentrations of triglycerides were all upheld - and various health claims for Vitamin E were also approved, relating to its ability to protect DNA, proteins and lipids against oxidative damage.
While the EFSA panel rejected some health claims relating to conjugated linoleic acid (CLA), it did not give any specific opinion about the relationship between CLA and body fat reduction. Cognis' Tonalin® CLA is marketed not as a weight loss ingredient, but rather as an ingredient for body fat reduction - a benefit that has been proven in numerous human studies, conducted to the strictest standards and designed using double-blind randomization and placebo control. "This is why we will review the opinion in detail and raise our concerns with the European Commission to clarify whether our claims will be evaluated in a later batch," says Dr. Arne Ptock, Global Product Line Manager Tonalin®, Cognis Nutrition & Health.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.